Trial Profile
Phase I/IIa, Single-Arm, Open Study of Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Rivoceranib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 01 Dec 2017 Results (n=10) assessing safety and efficacy published in the Medicine
- 14 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 14 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.